While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more ...

Weight-loss jabs, such as Ozempic, Wegovy and Mounjaro, have quickly earned a glowing global reputation for shifting the ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Some users experience side-effects such as nausea, diarrhoea and fatigue. Other clinical studies have found that some patients taking weight-loss drugs lose muscle at far faster rates than those ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

New poll shows about half of U.S. adults believe it is a good thing for adults to use weight-loss drugs if they are ...

Weight loss injections are prescription medications to ... is in the glucagon-like peptide-1 receptor agonist (GLP-1) drug class approved for use in type 2 diabetes. A doctor may also prescribe ...

Previously, the drugs were able to be prescribed through an email chat, from questionnaires or by people sending in photos of ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Cost is a major obstacle for many. The drugs can be expensive without insurance, with out-of-pocket expenses reaching ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...